Search		GO	Type Size:				Print This Page
Important Safety Information Full Prescribing Information

This information is intended for US healthcare professionals

Vaprisol Offers Proven Efficacy

Vaprisol provides prompt increases in serum sodium concentration, as well as effective water clearance.¹ Patients receiving Vaprisol also demonstrate increases in serum sodium concentration that are maintained for up to 30 days post treatment.^1*

Vaprisol has been available since 2006, and physicians have recognized Vaprisol as a valuable treatment option for euvolemic and hypervolemic hyponatremia. Vaprisol is conveniently packaged in single-use containers and can be stored right where it's needed.^†

*The effect of Vaprisol on maintenance of serum sodium concentration is not known.
^†Maintain at room temperature and protect from light until ready for use.

NEXT: Vaprisol: Prompt Efficacy

Reference: 1. Vaprisol Prescribing Information. Astellas Pharma US, Inc.

Stay Informed

Click here

Vaprisol Works Differently—Find Out How

Learn more about how first-in-class Vaprisol targets AVP to lower serum [Na⁺].

Click Here

Using Vaprisol in Your Patients

Learn how to use Vaprisol in a wide range of patients with dilutional hyponatremia.

Click here

Indication

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients
Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events

Important Safety Information

Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated
Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae
The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients
The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day, respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20 mg/day and 40 mg/day, respectively